ReviewCell communication and signaling : CCS2026
IQGAP3, the overlooked oncogenic twin of IQGAP1: mapping its interactome and functional roles across cellular signaling and cancer.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IQGAP3, the most recently identified member of the IQGAP family of scaffolding proteins, is increasingly recognized as a key regulator of oncogenic signaling networks that govern tumor initiation and progression. IQGAP3 integrates multiple signaling pathways including RAS/MAPK, PI3K/AKT, Wnt/β-catenin, Hedgehog, ATM/Chk2-ATR/Chk1, and TGF-β, thereby modulating cellular processes such as proliferation, DNA repair, genomic stability, epithelial to mesenchymal transition, metastasis, stemness, and resistance to therapy.This review offers a comprehensive overview of IQGAP3, beginning with its genomic organization and structural domains that underlie its distinct regulatory functions. We examine the physiological roles of IQGAP3 in cell cycle control, cytoskeletal organization, and early embryonic development, as well as its extensive network of interacting partners that link signaling pathways to specific cellular outcomes. We then highlight accumulating evidence implicating IQGAP3 dysregulation in oncogenesis, where it promotes tumor initiation, progression, and metastasis. Its contribution to therapy resistance further emphasizes its impact on clinical outcomes.In conclusion, by integrating current insights into the IQGAP3 interactome and associated signaling networks, we position IQGAP3 as a central signaling hub at the intersection of normal cellular physiology and malignant transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.